KPF_Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study_APCRA
The files and .R scripts here are provided to aid in understanding and reproduction of the analyses in the submitted paper, "Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study."
The scripts in the .R folder reference source files in the other folders.
This dataset is associated with the following publication:
Friedman, K., M. Gagne, L. Loo, P. Karamertzanis, T. Netzeva, T. Sobanski, J. Franzosa, A. Richard, R. Lougee, A. Gissi, J.J. Lee, M. Angrish, J. Dorne, S. Foster, K. Raffaele, T. Bahadori, M. Gwinn, J. Lambert, M. Whelan, M. Rasenberg, T. Barton-Maclaren, and R. Thomas. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. TOXICOLOGICAL SCIENCES. Society of Toxicology, RESTON, VA, 173(1): 202-225, (2020).
Resources
1 resource available
-
https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity
FILE
Complete Metadata
| accessLevel | public |
|---|---|
| bureauCode |
[
"020:00"
]
|
| contactPoint |
{
"fn": "Richard Judson",
"hasEmail": "mailto:judson.richard@epa.gov"
}
|
| description | The files and .R scripts here are provided to aid in understanding and reproduction of the analyses in the submitted paper, "Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study." The scripts in the .R folder reference source files in the other folders. This dataset is associated with the following publication: Friedman, K., M. Gagne, L. Loo, P. Karamertzanis, T. Netzeva, T. Sobanski, J. Franzosa, A. Richard, R. Lougee, A. Gissi, J.J. Lee, M. Angrish, J. Dorne, S. Foster, K. Raffaele, T. Bahadori, M. Gwinn, J. Lambert, M. Whelan, M. Rasenberg, T. Barton-Maclaren, and R. Thomas. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. TOXICOLOGICAL SCIENCES. Society of Toxicology, RESTON, VA, 173(1): 202-225, (2020). |
| distribution |
[
{
"title": "https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity",
"accessURL": "https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity"
}
]
|
| identifier | https://doi.org/10.23719/1503823 |
| keyword |
[
"ACToR",
"Threshold of Toxicological Concern (TTC)",
"high-throughput screening",
"high-throughput toxicokinetics",
"new approach methodologies",
"point of departure (POD)"
]
|
| license | https://pasteur.epa.gov/license/sciencehub-license.html |
| modified | 2019-06-04 |
| programCode |
[
"020:095"
]
|
| publisher |
{
"name": "U.S. EPA Office of Research and Development (ORD)",
"subOrganizationOf": {
"name": "U.S. Environmental Protection Agency",
"subOrganizationOf": {
"name": "U.S. Government"
}
}
}
|
| references |
[
"https://doi.org/10.1093/toxsci/kfz201"
]
|
| rights |
null
|
| title | KPF_Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study_APCRA |
